News Release

Company: Olympus Corporation

Yasuo Takeuchi, Director, Representative Executive Officer, President and CEO

(Code: 7733, First Section, Tokyo Stock Exchange)

Contact: Takaaki Sakurai, Vice President, Investor Relations

TEL: +81-3-3340-2111

## (Progress of disclosure matters)

Notice regarding completion of acquisition of Veran Medical Technologies, Inc. (to make it a subsidiary) in the United States

Olympus Corporation ("Olympus") hereby announces that as of December 29, 2020 (U.S. time) it has completed procedures to acquire Veran Medical Technologies, Inc., a high-growth company with a focus on the interventional pulmonology field\*<sup>1</sup>, through our consolidated subsidiary Olympus Corporation of the Americas, to make it a full subsidiary. The acquisition was originally announced in the timely disclosure "Notice regarding acquisition of Veran Medical Technologies, Inc. (to make it a subsidiary) in the United States." dated December 4, 2020.

### 1. Overview of the transferred subsidiary

(1)	Name	Veran Medical Technologies, Inc.
(2)	Address	St. Louis, MO, U.S.
(3)	Title and name of representative	CEO Jason Pesterfield
(4)	Description of business	Internal R&D & Manufacturing with some component and
		finished goods outsourcing
		Direct Sales in U.S.; Distributors leveraged internationally
(5)	Capital	6 million yen (Note 1)
(6)	Date of incorporation	August 7, 2003
(7)	Main shareholders and shareholding ratios	Versant Ventures, 20.54%, River Cities Capital, 17.61%,
		Maclellan Foundation, 12.70%

(Note 1) It is converted at  $USD1 = \frac{103.89}{100}$  (exchange rate as of the end of November 2020).

## 2. Date of acquisition

December 29, 2020

### 3. Acquisition amount

Approx. USD 340 million (Approx. ¥35.4 billion)

(Note 1) It is converted at  $USD1 = \frac{103.89}{1000}$  (exchange rate as of the end of November 2020).

(Note 2) The amount includes a conditional payment.

<sup>\*1:</sup> Treatment or diagnosis using bronchoscopes

# 4. Future outlook

Olympus is currently in the process of analyzing the impact of the acquisition, and we will promptly provide notice as soon as additional items to be disclosed have arisen.